STAAR Surgical director exercises 10,683 RSUs

STAAR Surgical director Jiang Wei reported equity compensation transactions involving company stock.

(Neutral)

(Neutral)How Sentiment works

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

How Sentiment works How the balance works

Form Type

Rhea-AI Filing Summary

STAAR Surgical director Jiang Wei reported equity compensation transactions involving company stock. On June 18, 2026, Jiang Wei exercised 10,683 previously granted restricted stock units into 10,683 shares of common stock, increasing direct common share holdings to 77,127 shares after the transactions.

On the same date, Jiang Wei received a new grant of 6,182 restricted stock units under the annual non-employee director equity compensation program for the 2026-2027 term. These new units are scheduled to vest in full on the earlier of June 18, 2027 or the 2027 Annual Meeting of Shareholders.

Insider Trade Summary

10,683 shares exercised/converted

Exercise 3 txns

Insider Jiang Wei

Role Director

Type	Security	Shares	Price	Value
Exercise	Restricted Stock Units	10,683	$0.00	$0.00
Grant/Award	Restricted Stock Units	6,182	$0.00	$0.00
Exercise	Common Stock	10,683	$0.00	$0.00

Holdings After Transaction: Restricted Stock Units — 6,182 contracts (Direct); Common Stock — 77,127 shares (Direct)

Footnotes (2)

F1. Reflects restricted stock units granted to the Reporting Person on June 18, 2025, pursuant to the Issuer's annual non-employee director equity compensation program for the 2025-2026 term, which vested on June 18, 2026.
F2. Reflects restricted stock units granted to the Reporting Person on June 18, 2026, pursuant to the Issuer's annual non-employee director equity compensation program for the 2026-2027 term. These equity awards vest in full on the earlier of June 18, 2027 or the Issuer's 2027 Annual Meeting of Shareholders.

Key Figures

RSUs exercised: 10,683 units New RSU grant: 6,182 units Shares held after transactions: 77,127 shares +2 more

5 metrics

RSUs exercised 10,683 units Restricted stock units converted to common stock on June 18, 2026

New RSU grant 6,182 units Annual non-employee director equity compensation for 2026-2027 term

Shares held after transactions 77,127 shares Direct common stock holdings following June 18, 2026 exercise

Exercise transactions 1 transaction, 10,683 shares Derivative exercise/conversion reported in transaction summary

Net buy/sell shares 0 shares No open-market buys or sales; neutral net direction

Key Terms

Restricted Stock Units, annual non-employee director equity compensation program, Exercise or conversion of derivative security, grant, award, or other acquisition

4 terms

Restricted Stock Units financial

"Reflects restricted stock units granted to the Reporting Person on June 18, 2025..."

Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.

annual non-employee director equity compensation program financial

"pursuant to the Issuer's annual non-employee director equity compensation program for the 2025-2026 term..."

Exercise or conversion of derivative security financial

"transaction_code_description: Exercise or conversion of derivative security"

grant, award, or other acquisition financial

"transaction_code_description: Grant, award, or other acquisition"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transactions did Jiang Wei report at STAAR Surgical (STAA)?

Jiang Wei exercised 10,683 restricted stock units into common shares and received a new grant of 6,182 restricted stock units. These actions are part of STAAR Surgical’s non-employee director equity compensation programs for consecutive board terms.

How many STAAR Surgical (STAA) shares does Jiang Wei hold after these transactions?

After the June 18, 2026 transactions, Jiang Wei directly holds 77,127 shares of STAAR Surgical common stock. This figure reflects the exercise of 10,683 restricted stock units into common shares reported in the Form 4 filing.

What is the size and vesting schedule of Jiang Wei’s new RSU grant at STAAR Surgical (STAA)?

Jiang Wei received 6,182 restricted stock units on June 18, 2026. These units vest in full on the earlier of June 18, 2027 or the company’s 2027 Annual Meeting of Shareholders, under the annual non-employee director equity compensation program.

Were Jiang Wei’s STAAR Surgical (STAA) transactions open-market buys or sales?

The reported transactions are equity compensation-related, not open-market buys or sales. They include the exercise of 10,683 previously granted restricted stock units into common stock and a new grant of 6,182 restricted stock units.

Which STAAR Surgical (STAA) director equity programs are referenced in Jiang Wei’s Form 4?

The Form 4 references STAAR Surgical’s annual non-employee director equity compensation programs for the 2025-2026 and 2026-2027 terms. One grant vested on June 18, 2026, and the new grant vests by June 18, 2027 or the 2027 annual meeting.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

Accepted by SEC EDGAR 06/22/2026 - 04:05 PM EDT

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Jiang Wei

(Last)

(First)

(Middle)

25510 COMMERCENTRE DRIVE

(Street)

LAKE FOREST

CALIFORNIA

92630

(City)

(State)

(Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
STAAR SURGICAL CO [ STAA ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director	10% Owner
	Officer (give title below)	Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
06/18/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
Common Stock⁽¹⁾	06/18/2026		M		10,683	A	$0	77,127	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
Restricted Stock Units⁽¹⁾	$0	06/18/2026		M			10,683	⁽¹⁾	⁽¹⁾	Common Stock	10,683	$0	0	D
Restricted Stock Units⁽²⁾	$0	06/18/2026		A		6,182		⁽²⁾	⁽²⁾	Common Stock	6,182	$0	6,182	D

Explanation of Responses:

1. Reflects restricted stock units granted to the Reporting Person on June 18, 2025, pursuant to the Issuer's annual non-employee director equity compensation program for the 2025-2026 term, which vested on June 18, 2026.

2. Reflects restricted stock units granted to the Reporting Person on June 18, 2026, pursuant to the Issuer's annual non-employee director equity compensation program for the 2026-2027 term. These equity awards vest in full on the earlier of June 18, 2027 or the Issuer's 2027 Annual Meeting of Shareholders.

Remarks:

This Form 4 reflects the equity awards granted to the Reporting Person on June 18, 2026 pursuant to Issuer's annual non-employee director equity compensation program for the 2026-2027 term.

	/s/ Kathleen Determann as attorney-in-fact for Jiang Wei	06/22/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Source: View Original Filing on SEC EDGAR